Skip to Content

Cysteamine Pregnancy and Breastfeeding Warnings

Cysteamine is also known as: Cystagon, Procysbi

Cysteamine Pregnancy Warnings

Studies in animals have shown reproductive toxicity, including teratogenesis and fetotoxicity at doses less than the recommended human maintenance dose. Observed teratogenic findings were cleft palate, kyphosis, heart ventricular septal defects, microcephaly, and exencephaly. There are no adequate and well controlled studies in pregnant women. AU TGA pregnancy category B3: Drugs which have been taken by only a limited number of pregnant women and women of childbearing age, without an increase in the frequency of malformation or other direct or indirect harmful effects on the human fetus having been observed. Studies in animals have shown evidence of an increased occurrence of fetal damage, the significance of which is considered uncertain in humans. US FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

UK: Use should be avoided during the first trimesters of pregnancy; use is not recommended unless clearly needed. AU, US: This drug should not be used during pregnancy unless the benefit outweighs the risk to the fetus. Comments: If a pregnancy is diagnosed or planned, the treatment should be carefully reconsidered and the patient must be advised of the possible teratogenic risks. AU TGA pregnancy category: B3 US FDA pregnancy category: C

See references

Cysteamine Breastfeeding Warnings

This drug reduced the survival of the offspring of adult rats dosed orally with 375 mg/kg/day (1.5 times the maximum recommended human dose based on body surface area).

UK: Use is contraindicated. US: Use is not recommended. Excreted into human milk: Unknown Excreted into animal milk: Yes

See references

References for pregnancy information

  1. "Product Information. Cystagon (cysteamine)." Mylan Pharmaceuticals, Morgantown, WV.
  2. Cerner Multum, Inc. "Australian Product Information." O 0
  3. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  4. "Product Information. Procysbi (cysteamine)." Raptor Pharmaceutical Corporation, Novato, CA.

References for breastfeeding information

  1. "Product Information. Procysbi (cysteamine)." Raptor Pharmaceutical Corporation, Novato, CA.
  2. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  3. Cerner Multum, Inc. "Australian Product Information." O 0
  4. "Product Information. Cystagon (cysteamine)." Mylan Pharmaceuticals, Morgantown, WV.

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.